ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

NCT07813572 · tracked via the Priya Life Science China tracker

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase

Phase 3

Started

2026-09

Last updated

2026-09-10

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

ZG005 for InjectionBevacizumab ( Avastin)SintilimabBevacizumab

ZG005 for Injection: Participants receive ZG005 20 mg/kg IV, Q3W

Bevacizumab ( Avastin): Participants receive Bevacizumab ( Avastin) 15 mg/kg IV, Q3W

Sintilimab: Participants receive Sintilimab 200mg IV, Q3W

Bevacizumab: Participants receive Bevacizumab 15 mg/kg IV, Q3W

Study summary

The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants with histologically/cytologically confirmed unresectable or metastatic advanced HCC; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Barcelona Clinic Liver Cancer stage B, not suitable for local treatment and BCLC C. * At least one measurable lesion based on Recist1.1. * No prior systemic therapy for HCC. * Child-Pugh ≤6 , no history of hepatic encephalopathy. Exclusion Criteria: * Active Central nervous system (CNS) metastasis or leptomeningeal metastases. * Any condition that is not suitable for participate in this study as determined by investigator.

Primary outcome measure(s)

Progression-free survival (PFS) — up to 3 years
PFS evaluated by the Blinded Independent Review Committee (IRC) based on RECIST V1.1
Overall survival (OS) — up to 5 years

Trial sites (1)

Facility	City	Region	Status
Nanjing Tianyinshan Hospital	Nanjing	Jiangsu

On this site

📄 Avastin (bevacizumab) drug profile →

More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Recruiting

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Recruiting

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma Recruiting

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. Recruiting

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer Recruiting

Other trials for the same condition

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing Recruiting

Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study Starting soon

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial Recruiting

HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07813572 on ClinicalTrials.gov ↗ ← All trials in China